Journal of Clinical Oncology, Vol 22, No 9 (May 1), 2004: pp. 1572-1582
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.10.042
Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer
A North Central Cancer Treatment Group Study
Megan M. Garrity,
Lawrence J. Burgart,
Michelle R. Mahoney,
Harold E. Windschitl,
Muhammad Salim,
Martin Wiesenfeld,
James E. Krook,
John C. Michalak,
Richard M. Goldberg,
Michael J. O'Connell,
Alfred F. Furth,
Daniel J. Sargent,
Linda M. Murphy,
Eunice Hill,
Darren L. Riehle,
Cecelia H. Meyers,
Thomas E. Witzig
From the Mayo Clinic and Mayo Foundation, Rochester; CentraCare Clinic, St Cloud; The Duluth Clinic, Duluth, MN; Cedar Rapids Oncology Project CCOP, Cedar Rapids; Siouxland Hematology-Oncology Associates, Sioux City, IA; University of North Carolina Department of Hematology/Oncology, Chapel Hill, NC; Allegheny General Hospital, Pittsburgh, PA; and Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
Address reprint requests to Thomas E. Witzig, MD, 6-28 Stabile Building, 200 First St SW, Rochester, MN 55905; e-mail: witzig{at}mayo.edu
PURPOSE: Molecular studies of colon cancer have provided insights into pathogenesis, yet it is unclear how important these markers are in predicting prognosis. This study investigated the prognostic significance of TUNEL, bcl-2, p53, proliferation marker Ki-67 and DNA mismatch repair (MMR) status in patients with Dukes' stage B2 and C colorectal adenocarcinomas.
PATIENTS AND METHODS: Tumor tissue from 366 patients (75% Dukes' C, 25% Dukes' B2) from four randomized North Central Cancer Treatment Group phase III surgical adjuvant trials were used. Eighty-one percent of patients received adjuvant treatment, which was primarily fluorouracil (FU) based (90%). Tumor location was predominantly (87%) the colon. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL), Ki-67, p53, bcl-2, and MMR were assayed using immunohistochemistry. Stage, grade, MMR, Ki-67, and previously determined flow cytometry markers (ploidy and S phase) were explored for associations with each other and with overall survival (OS) and disease-free survival (DFS).
RESULTS: Univariately, stage B2, low grade, diploid, Ki-67 more than 27%, normal p53, and FU-based adjuvant treatment were significantly associated with improved OS and DFS (P < .05). After adjusting for stage, grade, and ploidy in multivariate analysis, Ki-67 remained significantly related to both OS and DFS (P < .01). Active FU-based adjuvant treatment was significant only for OS in this multivariate model. Neither bcl-2 nor TUNEL were significant.
CONCLUSION: This retrospective study indicates that Ki-67 and ploidy may have stronger prognostic impact on OS and DFS than other parameters investigated after adjusting for stage and tumor grade. Prospective studies to elucidate the mechanism and prognostic significance of these findings are necessary.
Supported by the National Cancer Institute Grant (CA78899) and conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.
Presented as an abstract for oral presentation at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002.
Work for this study was completed at the Mayo Clinic, Rochester, MN.
Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Zaanan, P. Cuilliere-Dartigues, A. Guilloux, Y. Parc, C. Louvet, A. de Gramont, E. Tiret, S. Dumont, B. Gayet, P. Validire, et al.
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin
Ann. Onc.,
October 15, 2009;
(2009)
mdp383v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. T. Bosman, P. Yan, S. Tejpar, R. Fiocca, E. Van Cutsem, R. D. Kennedy, D. Dietrich, and A. Roth
Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment Trial
Clin. Cancer Res.,
September 1, 2009;
15(17):
5528 - 5533.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Sato, T. Suzuki, Y. Katayose, K. Miura, K. Shiiba, H. Tateno, Y. Miki, J. Akahira, Y. Kamogawa, S. Nagasaki, et al.
Steroid Sulfatase and Estrogen Sulfotransferase in Colon Carcinoma: Regulators of Intratumoral Estrogen Concentrations and Potent Prognostic Factors
Cancer Res.,
February 1, 2009;
69(3):
914 - 922.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. T. Sofocleous, R. G. Nascimento, L. M. Petrovic, D. S. Klimstra, M. Gonen, K. T. Brown, L. A. Brody, A. M. Covey, R. H. Thornton, Y. Fong, et al.
Histopathologic and Immunohistochemical Features of Tissue Adherent to Multitined Electrodes after RF Ablation of Liver Malignancies Can Help Predict Local Tumor Progression: Initial Results
Radiology,
October 1, 2008;
249(1):
364 - 374.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. A. Sinicrope, R. L. Rego, K. Okumura, N. R. Foster, M. J. O'Connell, D. J. Sargent, and H. E. Windschitl
Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas
Clin. Cancer Res.,
September 15, 2008;
14(18):
5810 - 5818.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A Walther, R Houlston, and I Tomlinson
Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis
Gut,
July 1, 2008;
57(7):
941 - 950.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. A. Sinicrope, R. L. Rego, N. R. Foster, S. N. Thibodeau, S. R. Alberts, H. E. Windschitl, and D. J. Sargent
Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers
Clin. Cancer Res.,
July 1, 2008;
14(13):
4128 - 4133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Zlobec, K. Baker, P. Minoo, J. R. Jass, L. Terracciano, and A. Lugli
Node-Negative Colorectal Cancer at High Risk of Distant Metastasis Identified by Combined Analysis of Lymph Node Status, Vascular Invasion, and Raf-1 Kinase Inhibitor Protein Expression
Clin. Cancer Res.,
January 1, 2008;
14(1):
143 - 148.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Zlobec, R. Steele, L. Terracciano, J. R Jass, and A. Lugli
Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer
J. Clin. Pathol.,
October 1, 2007;
60(10):
1112 - 1116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gill, A. W. Blackstock, and R. M. Goldberg
Colorectal Cancer
Mayo Clin. Proc.,
January 1, 2007;
82(1):
114 - 129.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Y. Locker, S. Hamilton, J. Harris, J. M. Jessup, N. Kemeny, J. S. Macdonald, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
J. Clin. Oncol.,
November 20, 2006;
24(33):
5313 - 5327.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Galle, D. Sittig, I. Hanisch, M. Wobus, E. Wandel, M. Loeffler, and G. Aust
Individual Cell-Based Models of Tumor-Environment Interactions: Multiple Effects of CD97 on Tumor Invasion
Am. J. Pathol.,
November 1, 2006;
169(5):
1802 - 1811.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. A. Sinicrope, R. L. Rego, K. C. Halling, N. R. Foster, D. J. Sargent, B. La Plant, A. J. French, C. J. Allegra, J. A. Laurie, R. M. Goldberg, et al.
Thymidylate synthase expression in colon carcinomas with microsatellite instability.
Clin. Cancer Res.,
May 1, 2006;
12(9):
2738 - 2744.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Lyall, S. R. Dundas, S. Curran, and G. I. Murray
Profiling Markers of Prognosis in Colorectal Cancer
Clin. Cancer Res.,
February 15, 2006;
12(4):
1184 - 1191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. McDermott, D. B. Longley, L. Galligan, W. Allen, T. Wilson, and P. G. Johnston
Effect of p53 Status and STAT1 on Chemotherapy-Induced, Fas-Mediated Apoptosis in Colorectal Cancer
Cancer Res.,
October 1, 2005;
65(19):
8951 - 8960.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-C. Kwon, C. H. Moon, S.-H. Kim, H.-J. Choi, H.-S. Lee, M. S. Roh, T.-H. Hwang, J.-S. Kim, and H.-J. Kim
Expression of Double-stranded RNA-activated Protein kinase (PKR) and its Prognostic Significance in Lymph Node Negative Rectal Cancer
Jpn. J. Clin. Oncol.,
September 1, 2005;
35(9):
545 - 550.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. P. de Jong, A. S.H. Gouw, P. M.J.G. Peeters, M. Bulthuis, L. Menkema, R. J. Porte, M. J.H. Slooff, H. van Goor, and A. van den Berg
P53 Mutation Analysis of Colorectal Liver Metastases: Relation to Actual Survival, Angiogenic Status, and p53 Overexpression
Clin. Cancer Res.,
June 1, 2005;
11(11):
4067 - 4073.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Michael and M.M. Doherty
Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy
J. Clin. Oncol.,
January 1, 2005;
23(1):
205 - 229.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Ravi, A. J. Jain, R. D. Schulick, V. Pham, T. S. Prouser, H. Allen, E. G. Mayer, H. Yu, D. M. Pardoll, A. Ashkenazi, et al.
Elimination of Hepatic Metastases of Colon Cancer Cells via p53-Independent Cross-Talk between Irinotecan and Apo2 Ligand/TRAIL
Cancer Res.,
December 15, 2004;
64(24):
9105 - 9114.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|